Synonyms: example 108 [US9655900B2] | TAK-931 | TAK931
Compound class:
Synthetic organic
Comment: Simurosertib (TAK-931) is an oral Cdc7 (cell division cycle 7-related protein kinase) inhibitor that is being developed by Millennium Pharmaceuticals/Takeda for potential antineoplastic activity in CDC7-overexpressing tumour cells [3]. Cdc7 is a serine/threonine kinase and cell division cycle protein. Simurosertib sensitizes tumour cells to DNA-damaging chemotherapies by functioning to disrupt the cells' ability to recover from DNA damage [2].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one |
International Nonproprietary Names ![]() |
|
INN number | INN |
11008 | simurosertib |
Synonyms ![]() |
example 108 [US9655900B2] | TAK-931 | TAK931 |
Database Links ![]() |
|
CAS Registry No. | 1330782-76-7 (source: WHO INN record) |
GtoPdb PubChem SID | 381744998 |
PubChem CID | 135564531 |
RCSB PDB Ligand | O1V |
Search Google for chemical match using the InChIKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |
Search Google for chemicals with the same backbone | XGVXKJKTISMIOW |
Search PubMed clinical trials | simurosertib |
Search PubMed titles | simurosertib |
Search PubMed titles/abstracts | simurosertib |
UniChem Compound Search for chemical match using the InChIKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |